SCHEMBL5544055

SCHEMBL5544055

[CH2]c1ccccc1NCc1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
L3MBTL1 Q9Y468 4/20 0.36
MAPK1 P28482 1/20 0.36
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
KMT2A Q03164 3/20 0.34
LMNA P02545 1/20 0.34
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
MEN1 O00255 2/20 0.33
IDO1 P14902 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
ACLY P53396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545206 0.85 MAPT (0.41) MAPTL3MBTL1MAPK1GAAKDM4E
SCHEMBL11511974 0.83 MAPT (0.47) MAPTL3MBTL1MAPK1GAAKDM4E
SCHEMBL5544240 0.83 LMNA (0.47) MAPTL3MBTL1MAPK1KMT2ALMNA
SCHEMBL5535113 0.82 ACLY (0.48) MAPTL3MBTL1GAAKDM4EKMT2A
SCHEMBL5539503 0.76 MAPT (0.55) MAPTL3MBTL1GAAKDM4EKMT2A
SCHEMBL5539354 0.76 CHRM2 (0.51) MAPTKMT2ALMNAMRGPRX4CYP1A2
SCHEMBL5544370 0.76 SSTR3 (0.51) MAPTL3MBTL1GAAKDM4EALDH1A1
SCHEMBL5535837 0.74 CA12 (0.33) MAPTL3MBTL1MAPK1KDM4EKMT2A
SCHEMBL5545072 0.74 L3MBTL1 (0.42) MAPTL3MBTL1MAPK1GAAKDM4E
SCHEMBL5542074 0.74 MAPT (0.40) MAPTMAPK1GAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885L3MBTL1 1931/4885MAPK1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.